Arcturus sues AbbVie over Capstan-related trade secrets claimnews2025-09-24T18:43:11+00:00September 24th, 2025|Endpoints News|
FDA unveils trio of new draft guidances to help cell and gene therapy developersnews2025-09-24T17:30:04+00:00September 24th, 2025|Endpoints News|
Hengrui, Glenmark ink ADC deal; Rome Therapeutics to seek ‘strategic options’news2025-09-24T14:30:23+00:00September 24th, 2025|Endpoints News|
Acadia discards nasal Prader-Willi drug after Phase 3 washoutnews2025-09-24T13:51:34+00:00September 24th, 2025|Endpoints News|
Harmony Biosciences’ cannabidiol drug fails Phase 3 trial in fragile Xnews2025-09-24T13:31:24+00:00September 24th, 2025|Endpoints News|
RA and Forbion back Sparrow’s $95M Series B for type 2 diabetes drugnews2025-09-24T12:30:41+00:00September 24th, 2025|Endpoints News|
With successful trial, uniQure eyes 2026 launch for Huntington’s gene therapynews2025-09-24T11:26:50+00:00September 24th, 2025|Endpoints News|
Biogen gets ‘unexpected’ CRL for high-dose Spinraza, will submit more technical datanews2025-09-24T11:08:55+00:00September 24th, 2025|Endpoints News|
Gates, Clinton orgs team up with Indian manufacturers to make $40 generic of Gilead’s twice-yearly PrEP drugnews2025-09-24T11:00:26+00:00September 24th, 2025|Endpoints News|
Sanofi adds $625M to its corporate venture armnews2025-09-24T05:00:16+00:00September 24th, 2025|Endpoints News|
